Zhenhua Zhao
Research Subjects
Zhenhua Zhao has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Fanting Zhu1 shared publication
- Leshan Cai
The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, 515041. China
1 shared publication - Liu Tenglong1 shared publication
Qiaoxin Zhang
1 shared publication- Weiyuan Chen1 shared publication
- Xia Zhou
Department of Pharmacy Shantou University Medical College 515041 Shantou Guangdong China
1 shared publication
Latest Publications
- Open Access
- 20 October 2026
- Published by Elsevier in SSRN Electronic Journal
An ssDNA-triggered CRISPR-Cas12a-SERS molecular lock system enables amplification-free multiplex pathogen discrimination in nasopharyngeal swabs
Respiratory tract infections with co-infections involving viruses and bacteria pose major diagnostic challenges. Current methods lack the sensitivity, speed, and multiplexing capacity needed for rapid etiological differentiation. Here, we report a one-pot, amplification-free biosensor integrating CRISPR-Cas12a with surface-enhanced Raman spectroscopy (SERS) for multiplexed detection of SARS-CoV-2, Influenza A virus (FluA), and Haemophilus influenzae (HI). Three SERS-encoded Au nanoprobe pairs are labeled with distinct Raman reporters (4-MBA at 1078 cm-1 for SARS-CoV-2, DTNB at 1325 cm-1 for FluA, and MMC at 1168 cm-1 for HI). The single-stranded DNA (ssDNA) linker is designed to hybridize with probe pairs, inducing aggregation and signal quenching after centrifugation. Target binding activates Cas12a trans-cleavage, preventing probe aggregation and yielding a “turn-on” SERS signal in the supernatant. The platform achieves detection limits of 10 copies/mL for SARS-CoV-2 and FluA, and 100 copies/mL for HI, with a six-order linear range (R2>0.99), high specificity, and reproducibility (RSD<10%). In 50 clinical nasopharyngeal swabs, it shows 100% concordance with qPCR for viral targets and with mass spectrometry for HI. This work demonstrates that CRISPR-SERS integration offers a powerful, multiplexable, and instrument-simplified solution for respiratory infection diagnosis, particularly suitable for point-of-care diagnosis of respiratory co-infections.
- 20 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAn ssDNA-triggered CRISPR-Cas12a-SERS molecular lock system enables amplification-free multiplex pathogen discrimination in nasopharyngeal swabs
Respiratory tract infections with co-infections involving viruses and bacteria pose major diagnostic challenges. Current methods lack the sensitivity, speed, and multiplexing capacity needed for rapid etiological differentiation. Here, we report a one-pot, amplification-free biosensor integrating CRISPR-Cas12a with surface-enhanced Raman spectroscopy (SERS) for multiplexed detection of SARS-CoV-2, Influenza A virus (FluA), and Haemophilus influenzae (HI). Three SERS-encoded Au nanoprobe pairs are labeled with distinct Raman reporters (4-MBA at 1078 cm-1 for SARS-CoV-2, DTNB at 1325 cm-1 for FluA, and MMC at 1168 cm-1 for HI). The single-stranded DNA (ssDNA) linker is designed to hybridize with probe pairs, inducing aggregation and signal quenching after centrifugation. Target binding activates Cas12a trans-cleavage, preventing probe aggregation and yielding a “turn-on” SERS signal in the supernatant. The platform achieves detection limits of 10 copies/mL for SARS-CoV-2 and FluA, and 100 copies/mL for HI, with a six-order linear range (R2>0.99), high specificity, and reproducibility (RSD<10%). In 50 clinical nasopharyngeal swabs, it shows 100% concordance with qPCR for viral targets and with mass spectrometry for HI. This work demonstrates that CRISPR-SERS integration offers a powerful, multiplexable, and instrument-simplified solution for respiratory infection diagnosis, particularly suitable for point-of-care diagnosis of respiratory co-infections.